Data for GAW20: genome-wide DNA sequence variation and epigenome-wide DNA methylation before and after fenofibrate treatment in a family study of metabolic phenotypes
Abstract GAW20 provided participants with an opportunity to comprehensively examine genetic and epigenetic variation among related individuals in the context of drug treatment response. GAW20 used data from 188 families (N = 1105) participating in the Genetics of Lipid Lowering Drugs and Diet Networ...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-09-01
|
Series: | BMC Proceedings |
Online Access: | http://link.springer.com/article/10.1186/s12919-018-0114-0 |
id |
doaj-73370670bd7b4b159967e4a50ca741c7 |
---|---|
record_format |
Article |
spelling |
doaj-73370670bd7b4b159967e4a50ca741c72020-11-25T02:01:05ZengBMCBMC Proceedings1753-65612018-09-0112S951010.1186/s12919-018-0114-0Data for GAW20: genome-wide DNA sequence variation and epigenome-wide DNA methylation before and after fenofibrate treatment in a family study of metabolic phenotypesStella Aslibekyan0Laura Almasy1Michael A. Province2Devin M. Absher3Donna K. Arnett4Department of Epidemiology, School of Public Health, University of Alabama at BirminghamDepartment of Biomedical and Health Informatics, Children’s Hospital of PhiladelphiaDivision of Statistical Genomics, Washington University in St LouisHudson Alpha Institute for BiotechnologyCollege of Public Health, University of KentuckyAbstract GAW20 provided participants with an opportunity to comprehensively examine genetic and epigenetic variation among related individuals in the context of drug treatment response. GAW20 used data from 188 families (N = 1105) participating in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study (clinicaltrials.gov identifier NCT00083369), which included CD4+ T-cell DNA methylation at 463,995 cytosine-phosphate-guanine (CpG) sites measured before and after a 3-week treatment with fenofibrate, single-nucleotide variation at 906,600 loci, metabolic syndrome components ascertained before and after the drug intervention, and relevant covariates. All GOLDN participants were of European descent, with an average age of 48 years. In addition, approximately half were women and approximately 40% met the diagnostic criteria for metabolic syndrome. Unique advantages of the GAW20data set included longitudinal (3 weeks apart) measurements of DNA methylation, the opportunity to explore the contributions of both genotype and DNA methylation to the interindividual variability in drug treatment response, and the familial relationships between study participants. The principal disadvantage of GAW20/GOLDN data was the spurious correlation between batch effects and fenofibrate effects on methylation, which arose because the pre- and posttreatment methylation data were generated and normalized separately, and any attempts to remove time-dependent technical artifacts would also remove biologically meaningful changes brought on by fenofibrate. Despite this limitation, the GAW20 data set offered informative, multilayered omics data collected in a large population-based study of common disease traits, which resulted in creative approaches to integration and analysis of inherited human variation.http://link.springer.com/article/10.1186/s12919-018-0114-0 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Stella Aslibekyan Laura Almasy Michael A. Province Devin M. Absher Donna K. Arnett |
spellingShingle |
Stella Aslibekyan Laura Almasy Michael A. Province Devin M. Absher Donna K. Arnett Data for GAW20: genome-wide DNA sequence variation and epigenome-wide DNA methylation before and after fenofibrate treatment in a family study of metabolic phenotypes BMC Proceedings |
author_facet |
Stella Aslibekyan Laura Almasy Michael A. Province Devin M. Absher Donna K. Arnett |
author_sort |
Stella Aslibekyan |
title |
Data for GAW20: genome-wide DNA sequence variation and epigenome-wide DNA methylation before and after fenofibrate treatment in a family study of metabolic phenotypes |
title_short |
Data for GAW20: genome-wide DNA sequence variation and epigenome-wide DNA methylation before and after fenofibrate treatment in a family study of metabolic phenotypes |
title_full |
Data for GAW20: genome-wide DNA sequence variation and epigenome-wide DNA methylation before and after fenofibrate treatment in a family study of metabolic phenotypes |
title_fullStr |
Data for GAW20: genome-wide DNA sequence variation and epigenome-wide DNA methylation before and after fenofibrate treatment in a family study of metabolic phenotypes |
title_full_unstemmed |
Data for GAW20: genome-wide DNA sequence variation and epigenome-wide DNA methylation before and after fenofibrate treatment in a family study of metabolic phenotypes |
title_sort |
data for gaw20: genome-wide dna sequence variation and epigenome-wide dna methylation before and after fenofibrate treatment in a family study of metabolic phenotypes |
publisher |
BMC |
series |
BMC Proceedings |
issn |
1753-6561 |
publishDate |
2018-09-01 |
description |
Abstract GAW20 provided participants with an opportunity to comprehensively examine genetic and epigenetic variation among related individuals in the context of drug treatment response. GAW20 used data from 188 families (N = 1105) participating in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study (clinicaltrials.gov identifier NCT00083369), which included CD4+ T-cell DNA methylation at 463,995 cytosine-phosphate-guanine (CpG) sites measured before and after a 3-week treatment with fenofibrate, single-nucleotide variation at 906,600 loci, metabolic syndrome components ascertained before and after the drug intervention, and relevant covariates. All GOLDN participants were of European descent, with an average age of 48 years. In addition, approximately half were women and approximately 40% met the diagnostic criteria for metabolic syndrome. Unique advantages of the GAW20data set included longitudinal (3 weeks apart) measurements of DNA methylation, the opportunity to explore the contributions of both genotype and DNA methylation to the interindividual variability in drug treatment response, and the familial relationships between study participants. The principal disadvantage of GAW20/GOLDN data was the spurious correlation between batch effects and fenofibrate effects on methylation, which arose because the pre- and posttreatment methylation data were generated and normalized separately, and any attempts to remove time-dependent technical artifacts would also remove biologically meaningful changes brought on by fenofibrate. Despite this limitation, the GAW20 data set offered informative, multilayered omics data collected in a large population-based study of common disease traits, which resulted in creative approaches to integration and analysis of inherited human variation. |
url |
http://link.springer.com/article/10.1186/s12919-018-0114-0 |
work_keys_str_mv |
AT stellaaslibekyan dataforgaw20genomewidednasequencevariationandepigenomewidednamethylationbeforeandafterfenofibratetreatmentinafamilystudyofmetabolicphenotypes AT lauraalmasy dataforgaw20genomewidednasequencevariationandepigenomewidednamethylationbeforeandafterfenofibratetreatmentinafamilystudyofmetabolicphenotypes AT michaelaprovince dataforgaw20genomewidednasequencevariationandepigenomewidednamethylationbeforeandafterfenofibratetreatmentinafamilystudyofmetabolicphenotypes AT devinmabsher dataforgaw20genomewidednasequencevariationandepigenomewidednamethylationbeforeandafterfenofibratetreatmentinafamilystudyofmetabolicphenotypes AT donnakarnett dataforgaw20genomewidednasequencevariationandepigenomewidednamethylationbeforeandafterfenofibratetreatmentinafamilystudyofmetabolicphenotypes |
_version_ |
1724958952714665984 |